Bird Rock Bio is focused on the discovery and development of novel biologic therapeutics that meet the medical and commercial needs for China’s patients and healthcare system and that have the potential to be disruptive globally. RYI-008 is a novel, extremely potent monoclonal antibody that is highly selective to IL-6, a cytokine widely implicated in inflammation and cancer. In addition to RYI-008, RuiYi has a growing pipeline of monoclonal antibodies from its internal discovery efforts utilizing a series of the Company’s technologies, including the iCAP (intramembranous Conformation Antigen Presenting) system. Targets include a select subset of G protein coupled receptors (GPCR), where specificity in binding is critical but has proven difficult to achieve with small molecule modulators.
|HQ||San Diego, CA, US||Map|
|Employees (est.) (Sept 2021)||3|
Bird Rock Bio total Funding
Bird Rock Bio latest funding size
Time since last funding
|6 years ago|
Bird Rock Bio investors
|Versant Ventures, SR One, 5AM Ventures, Aravis Ventures, Apposite Capital, Merck Ventures, AM Ventures|
Bird Rock Bio has 254 Twitter Followers. The number of followers has increased 0.1% month over month and decreased 1% quarter over quarter
When was Bird Rock Bio founded?
Bird Rock Bio was founded in 2002.
Who are Bird Rock Bio key executives?
Bird Rock Bio's key executives are Paul A. Grayson, Alan Glicklich and Anke Kretz-Rommel.
How many employees does Bird Rock Bio have?
Bird Rock Bio has 3 employees.
Who are Bird Rock Bio competitors?
Competitors of Bird Rock Bio include Cell Signaling Technology, Ginkgo Bioworks and Unither Pharmaceuticals.
Where is Bird Rock Bio headquarters?
Bird Rock Bio headquarters is located at 2223 Avenida De La Playa #205, La Jolla, San Diego.
Where are Bird Rock Bio offices?
Bird Rock Bio has an office in San Diego.
How many offices does Bird Rock Bio have?
Bird Rock Bio has 1 office.
Receive alerts for 300+ data fields across thousands of companies